<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        34-249-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZILDAFIT 10 MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMLODIPINE BESILATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="APOTEX" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            APOTEX
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C08CA01 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- How APO-AMLODIPINE works</strong><br />APO-AMLODIPINE contains the active substance amlodipine which belongs to a group of medicines called calcium antagonists.</p><p>APO-AMLODIPINE is used to treat high blood pressure (hypertension) or a certain type of chest pain called angina, a rare form of which is Prinzmetal&rsquo;s or variant angina.</p><p>In patients with high blood pressure your medicine works by relaxing blood vessels, so that blood passes through them more easily. In patients with angina APO-AMLODIPINE work by improving blood supply to the heart muscle which then receives more oxygen and as a result chest pain is prevented. Your medicine does not provide immediate relief of chest pain from angina.&nbsp;</p><p>&nbsp;</p><p><strong>b- Use in children and adolescents</strong></p><p>APO-AMLODIPINE have not been studied in children under the age of 6 years. APO-AMLODIPINE should only be used for hypertension in children and adolescents from 6 years to 17 years of age (see section 3- <strong>How to take APO-AMLODIPINE</strong>). For more information, talk to your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>a- Do not take APO-AMLODIPINE</strong></p><ul><li>If you are allergic (hypersensitive) to APO-AMLODIPINE or any of the other ingredients of your medicine listed in section 6, or to any other calcium antagonists. This may be itching, reddening of the skin or difficulty in breathing.</li><li>If you have severe low blood pressure (hypotension).</li><li>If you have narrowing of the aortic heart valve (aortic stenosis) or cardiogenic shock (a condition where your heart is unable to supply enough blood to the body).</li><li>If you suffer from heart failure after a heart attack.</li></ul><p>&nbsp;</p><p><strong>b- Take special care with APO-AMLODIPINE</strong></p><p>You should inform your doctor if you have or have had any of the following conditions:</p><ul><li>Recent heart attack</li><li>Heart failure</li><li>Severe increase in blood pressure (Hypertensive crisis)</li><li>Liver disease</li><li>You are elderly and your dose needs to be increased</li></ul><p>&nbsp;</p><p><strong>c- Taking APO-AMLODIPINE with other medicines, herbal or dietary supplements</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. APO-AMLODIPINE may affect or be affected by other medicines, such as:</p><ul><li>ketoconazole, itraconazole (anti-fungal medicines)</li><li>ritonavir, indinavir, nelfinavir (so called protease inhibitors used to treat HIV)</li><li>rifampicin, erythromycin, clarithromycin (antibiotics)&nbsp;</li><li>hypericum perforatum (St. John&rsquo;s Wort)</li><li>verapamil, diltiazem (heart medicines)</li><li>dantrolene (infusion for severe body temperature abnormalities)</li><li>simvastatin (lowers your blood cholesterol)</li></ul><p>APO-AMLODIPINE may lower your blood pressure even more if you are already taking other medicines to treat your high blood pressure.</p><p>&nbsp;</p><p><strong>d- Taking APO-AMLODIPINE with food and drink</strong></p><p>Grapefruit juice and grapefruit should not be consumed by people who are taking APO-AMLODIPINE. This is because grapefruit and grapefruit juice can lead to an increase in the blood levels of the active ingredient APO-AMLODIPINE, which can cause an unpredictable increase in the blood pressure lowering effect of APO-AMLODIPINE.</p><p>&nbsp;</p><p><strong>e- Pregnancy &amp; breast-feeding</strong></p><p>The safety of APO-AMLODIPINE in human pregnancy has not been established. If you think you might be pregnant, or are planning to get pregnant, you must tell your doctor before you take APO-AMLODIPINE. &nbsp;It is not known whether APO-AMLODIPINE is passed into breast milk. If you are breast-feeding or about to start breast-feeding you must tell your doctor before taking APO-AMLODIPINE.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p>&nbsp;</p><p><strong>f- Driving and using machines</strong></p><p>APO-AMLODIPINE may affect your ability to drive or use machines. If the tablets make you feel sick, dizzy or tired, or give you a headache, do not drive or use machines and contact your doctor immediately.</p><p>&nbsp;</p><p><strong>g- Important information about some of the ingredients of APO-AMLODIPINE</strong></p><p>This medicine contains lactose, if you are intolerant to lactose and if you think you are having an allergic reaction, do not take any more of the medicine and contact your doctor immediately or go to the Accident and Emergency department at the nearest hospital.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much APO-AMLODIPINE to take</strong><br />Always take your medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.&nbsp;</p><p>The usual initial dose is APO-AMLODIPINE 5 mg once daily. The dose can be increased to APO-AMLODIPINE 10 mg once daily. Your medicine can be used before or after food and drinks. You should take your medicine at the same time each day with a drink of water. Do not take APO-AMLODIPINE with grapefruit juice.<br />&nbsp;&nbsp; &nbsp;<br /><strong>Use in children and adolescents</strong></p><p>For children and adolescents (6 -17 years old), the recommended usual starting dose is 2.5 mg a day. The maximum recommended dose is 5 mg a day. APO-AMLODIPINE 2.5 mg is not currently available and the 2.5 mg dose cannot be obtained with APO-AMLODIPINE 5 mg as these tablets are not manufactured to break into two equal halves.</p><p>It is important to keep taking the tablets. Do not wait until your tablets are finished before seeing your doctor.</p><p>&nbsp;</p><p><strong>a- If you take more APO-AMLODIPINE than you should</strong></p><p>Taking too many tablets may cause your blood pressure to become low or even dangerously low. You may feel dizzy, lightheaded, faint or weak. If blood pressure drop is severe enough shock can occur. Your skin could feel cool and clammy and you could lose consciousness. Seek immediate medical attention if you take too many APO-AMLODIPINE.</p><p>&nbsp;</p><p><strong>b- If you forget to take APO-AMLODIPINE&nbsp;</strong></p><p>Do not worry. If you forget to take a tablet, leave out that dose completely. Take your next dose at the right time. Do not take a double dose to make up for a missed dose.</p><p>&nbsp;</p><p><strong>c- Do not stop taking APO-AMLODIPINE&nbsp;</strong></p><p>Your doctor will advise you how long to take your medicine. Your condition may return if you stop using your medicine before you are advised. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, APO-AMLODIPINE can cause side effects, although not everybody gets them.</p><p>Visit your doctor immediately if you experience any of the following very rare, severe side effects after taking this medicine.</p><ul><li>Sudden wheeziness, chest pain, shortness of breath or difficulty in breathing</li><li>Swelling of eyelids, face or lips</li><li>Swelling of the tongue and throat which causes great difficulty breathing</li><li>Severe skin reactions including intense skin rash, hives, reddening of the skin over your whole body, severe itching, blistering, peeling and swelling of the skin, inflammation of mucous membranes (Stevens Johnson Syndrome) or other allergic reactions</li><li>Heart attack, abnormal heart beat</li><li>Inflamed pancreas which may cause severe abdominal and back pain accompanied with feeling very unwell</li></ul><p>The following common side-effects have been reported. If any of these cause you problems or if they last for more than one week, you should contact your doctor.</p><p>&nbsp;</p><p><strong>Common: affects 1 to 10 users in 100</strong></p><ul><li>Headache, dizziness, sleepiness (especially at the beginning of treatment)</li><li>Palpitations (awareness of your heart beat), flushing</li><li>Abdominal pain, feeling sick (nausea)</li><li>Ankle swelling (oedema), tiredness</li></ul><p>Other side-effects that have been reported include the following list. If any of these get serious, or if you notice any side-effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p><p><strong>Uncommon: affects 1 to 10 users in 1,000</strong></p><ul><li>Mood changes, anxiety, depression, sleeplessness</li><li>Trembling, taste abnormalities, fainting, weakness</li><li>Numbness or tingling sensation in your limbs; loss of pain sensation</li><li>Visual disturbances, double vision, ringing in the ears</li><li>Low blood pressure</li><li>Sneezing/running nose caused by inflammation of the lining of the nose (rhinitis)</li><li>Altered bowel habits, diarrhoea, constipation, indigestion, dry mouth, vomiting (being sick)</li><li>Hair loss, increased sweating, itchy skin, red patches on skin, skin discolouration</li><li>Disorder in passing urine, increased need to urinate at night, increased number of times of passing urine</li><li>Inability to obtain an erection; discomfort or enlargement of the breasts in men</li><li>Weakness, pain, feeling unwell</li><li>Joint or muscle pain, muscle cramps, back pain</li><li>Weight increase or decrease</li></ul><p>&nbsp;</p><p><strong>Rare: affects 1 to 10 users in 10,000</strong></p><ul><li>Confusion</li></ul><p>&nbsp;</p><p><strong>Very rare: affects less than 1 user in 10,000</strong></p><ul><li>Decreased numbers of white blood cells, decrease in blood platelets which may result in unusual bruising or easy bleeding&nbsp;(red blood cell damage)</li><li>Excess sugar in blood (hyperglycemia)</li><li>A disorder of the nerves which can cause weakness, tingling or numbness</li><li>Cough, swelling of the gums</li><li>Abdominal bloating (gastritis)</li><li>Abnormal liver function, inflammation of the liver (hepatitis), yellowing of the skin (jaundice), liver enzyme increase which may have an effect on some medical tests</li><li>Increased muscle tension</li><li>Inflammation of blood vessels, often with skin rash</li><li>Sensitivity to light</li><li>Disorders combining rigidity, tremor, and/or movement disorders</li></ul><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>Keep out of the reach and sight of children.</li><li>Store below 30&deg;C.</li><li>Store in the original package in order to protect from light.</li><li>Do not use your medicine after the expiry date which is stated on the pack after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</li><li>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <ul><li>The active substance is amlodipine besylate.</li><li>The other ingredients are Microcrystalline cellulose, lactose monohydrate, maize starch and magnesium stearate (E470B).</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                APO-AMLODIPINE 5 mg, off-white to white round tablets. The tablets have the inscription “APO” on one side and the inscription “AML” and “5” on the other side.

APO-AMLODIPINE 5 mg available in aluminium/PVC/PVDC blister packs containing 28 and 30 tablets.

APO-AMLODIPINE 10 mg, off white to white round tablets. The tablets have the inscription “APO” on one side and the inscription “AML” and “10” on the other side. 

APO-AMLODIPINE 10 mg available in aluminium/PVC/PVDC blister packs containing 14 and 30 tablets.

* Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:&nbsp;</strong><br />Apotex Nederland BV Archimedesweg 2 2333 CN &nbsp;Leiden The Netherlands.</p><p><strong>Manufacturer:</strong><br />Apotex Inc., Toronto, Ontario, M9L 1T9 Canada.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>أ- كيفية عمل هذا الدواء</strong><br />تحتوي أبو-أملوديبين على المادة الفعالة أملوديبين والتي تنتمي إلى مجموعة من الأدوية تسمي مضادات الكاليسيوم.</p><p>وتستخدم زيلدافيت لعلاج ارتفاع ضغط الدم أو نوع معين من آلام الصدر المسماة الذبحة الصدرية، وهو نوع نادر منها ألا وهو ذبحة برنزميتال أو الذبحة الصدرية المتغيرة.</p><p>وبالنسبة لمرضى ارتفاع ضغط الدم، يعمل هذا الدواء عن طريق إرخاء الأوعية الدموية، بحيث يمر الدم من خلالها بسهولة أكبر. أما بالنسبة لمرضى الذبحة الصدرية، فتعمل زيلدافيت من خلال تحسين تدفق الدم إلى عضلة القلب والتي تتلقى بذلك مزيداً من الأوكسجين وكنتيجة لذلك تتم الوقاية من آلام الصدر. لا يحقق هذا الدواء تسكيناً فورياً لآلام الصدر الناشئة عن الذبحة الصدرية.</p><p>&nbsp;</p><p><strong>ب- استخدام الدواء في علاج الأطفال والمراهقين</strong></p><p>لم تتم دراسة استخدام زيلدافيت في علاج الأطفال ممن تقل أعمارهم عن 6 سنوات. وينبغي أن يقتصر استخدام زيلدافيت على علاج ارتفاع ضغط الدم لدى الأطفال والمراهقين ممن تتراوح أعمارهم من 6 إلى 17 عاماً (انظر الجزئية 3 طريقة استخدام زيلدافيت). لمزيد من المعلومات، تحدث إلى طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أ- لا تستخدم زيلدافيت</strong></p><ul><li>إذا كنت مصاباً بالحساسية (فرط الحساسية) لمادة أملوديبين أو غيرها من المكونات الأخرى لهذا العقار المدرجة في الجزئية 6 من هذه النشرة أو لأي مضادات كالسيوم أخرى. والتي قد تظهر كحكة أو احمرار بالجلد أو صعوبة في التنفس.</li><li>إذا كان لديك انخفاض شديد في ضغط الدم (انخفاض ضغط الدم).</li><li>إذا كان لديك ضيق في صمام القلب الأورطى (ضيق الأورطى) أو صدمة قلبية (حالة يكون فيها قلبك غير قادر على ضخ الدم إلى الجسم بقدر كافٍ).</li><li>إذا كنت تعاني من قصور في القلب عقب الإصابة بأزمة قلبية.</li></ul><p>&nbsp;</p><p><strong>ب- الاحتياطات عند استعمال زيلدافيت</strong></p><p>ينبغي عليك إبلاغ الطبيب إذا كنت مصاباً أو سبقت إصابتك بأي من الحالات التالية:</p><ul><li>أزمة قلبية حديثة</li><li>فشل القلب</li><li>ارتفاع شديد في ضغط الدم (أزمة ارتفاع ضغط الدم)</li><li>مرض كبدي</li><li>إذا كنت من كبار السن وتحتاج إلى زيادة الجرعة التي تتناولها.</li></ul><p>&nbsp;</p><p><strong>ج- التداخلات الدوائية من أخذ هذا المستحضر مع أي ادوية اخرى او اعشاب او مكملات غذائية</strong></p><p>يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حالياً أو تناولت مؤخرا أية أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p>وقد تؤثر زيلدافيت &nbsp;أو تتأثر بأدوية أخرى, مثل:</p><ul><li>كيتوكونازول، إيتراكونازول (أدوية مضادة للفطريات)&nbsp;</li><li>ريتونافير، اندينافير، نيلفينافير (المسماة مثبطات الأنزيم البروتيني وتستخدم لعلاج فيروس نقص المناعة البشرية)&nbsp;</li><li>ريفامبيسين، إريثروميسين، كلاريثروميسين &nbsp;(مضادات حيوية)&nbsp;</li><li>بيرفوراتوم هايبريكم (نبتة سانت جون)&nbsp;</li><li>فيراباميل، ديلتيازيم (أدوية قلبية)&nbsp;</li><li>دانترولين (تسريب وريدي لعلاج الاضطرابات الشديدة في درجة حرارة الجسم)</li><li>سيمفاستاتين (يخفض نسبة الكوليسترول في الدم)&nbsp;</li></ul><p>وقد تخفض زيلدافيت من ضغط الدم بدرجة أكبر إذا كنت تتناول بالفعل أدوية أخرى لعلاج ضغط الدم المرتفع لديك.</p><p>&nbsp;</p><p><strong>د- تناول زيلدافيت مع الطعام والشراب</strong></p><p>لا ينبغي تناول عصير الجريب فروت وفاكهة الجريب فروت من قبل الأشخاص الذين يتناولون زيلدافيت. ذلك لأن كلا من فاكهة الجريب فروت وعصير الجريب فروت &nbsp;يمكن أن يؤدي إلى زيادة في مستويات المادة الفعالة أملوديبين في الدم مما قد يسبب زيادة غير متوقعة في تأثير زيلدافيت المخفض لضغط الدم.</p><p>&nbsp;</p><p><strong>هـ- الحمل والرضاعة</strong></p><p>لم يتم التحقق من أمان استخدام زيلدافيت خلال فترة الحمل لدى البشر. فإذا ساورك شك بأنك حامل أو كنت تخططين للحمل، فلابد لك من إبلاغ الطبيب قبل تناول زيلدافيت. ليس معروفا ما إذا كان زيلدافيت يفرز في لبن الأم. فإذا كنت ترضعين طبيعيا أو على وشك أن تبدئي في الرضاعة الطبيعية، فلابد لك من إبلاغ الطبيب قبل تناول زيلدافيت.</p><p>اسأل طبيبك أو الصيدلي للحصول على المشورة قبل تناول أي دواء.</p><p>&nbsp;</p><p><strong>و- تأثيره على القيادة واستخدام الآلات</strong></p><p>قد يؤثر زيلدافيت على القدرة على القيادة أو استخدام الآلات. فإذا كانت الأقراص تجعلك تشعر بالإعياء أو بالدوار أو التعب أو بالصداع، فلا تقدم على القيادة أو استخدام الآلات واتصل بطبيبك على الفور.</p><p>&nbsp;</p><p><strong>&nbsp;ز- معلومات هامة حول بعض مكونات زيلدافيت</strong></p><p>هذا الدواء يحتوي على اللاكتوز، فإذا كنت لا تتقبل اللاكتوز، وإذا كنت تعتقد أنك تواجه رد فعل تحسسي، لا تأخذ أي شيء من الدواء واتصل بطبيبك على الفور أو الذهاب إلى قسم الحوادث والطوارئ في أقرب مستشفى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>كيف يستخدم زيلدافيت</strong></p><p>احرص دائما على تناول الدواء الخاص بك كما نصحك طبيبك على وجه الدقة. &nbsp;فإذا لم تكن متأكدا، توجب عليك مراجعة الطبيب أو الصيدلي. والجرعة المبدئية المعتادة من زيلدافيت هي 5 ملجم مرة واحدة يوميا. ويمكن زيادة جرعة &nbsp;زيلدافيت إلى 10 ملجم مرة واحدة يوميا. ويمكن استخدام هذا الدواء قبل أو بعد الطعام والمشروبات. يجب أن تتناول الدواء في نفس الموعد كل يوم مع شربة ماء. ولا تتناول زيلدافيت مع عصير الجريب فروت.<br />&nbsp;<br />استخدام الدواء في علاج الأطفال والمراهقين<br />الجرعة المبدئية المعتادة الموصى بها بالنسبة للأطفال والمراهقين ( 6-17 سنة) هي &nbsp;2.5 ملجم يوميا. وأقصى جرعة يسمح بها هي 5 ملجم يوميا. إن أقراص زيلدافيت 2.5 ملجم غير متوفرة حالياً ولا يمكن الحصول على جرعة 2.5 ملجم من زيلدافيت 5 ملجم &nbsp;لأن هذه الأقراص ليست مصنعة بحيث يمكن كسرها إلى نصفين متساويين.</p><p>من المهم المحافظة على تناول الأقراص. لا تنتظر حتى تنفد الأقراص الخاصة بك قبل زيارة طبيبك.</p><p>&nbsp;</p><p><strong>أ- الجرعة الزائدة من زيلدافيت</strong></p><p>إن تناول أقراص كثيرة جدا قد يسبب انخفاض ضغط الدم لديك أو حتى انخفاضه بصورة خطيرة. &nbsp;قد تشعر بالدوار أو الدوخة أو الإغماء أو الضعف. ويمكن أن تحدث الصدمة إذا انخفض ضغط الدم بشدة كافية. قد يصبح جلدك بارداً ورطباً وقد تفقد الوعي. التمس العناية الطبية على الفور إذا تناولت عددا كبيراً من زيلدافيت.</p><p>&nbsp;</p><p><strong>ب- نسيان تناول جرعة زيلدافيت</strong></p><p>لا تقلق. إذا نسيت تناول قرص، دعك من تلك الجرعة تماما. &nbsp;وتناول الجرعة التالية في الوقت الصحيح. لا تتناول جرعة مضاعفة لتعويض الجرعة الفائتة.</p><p>&nbsp;</p><p><strong>ج- لا تتوقف عن تناول زيلدافيت</strong></p><p>سوف ينصحك طبيبك بشأن مدة تناول الدواء. فقد تعود حالتك إذا توقفت عن تناول الدواء قبل أن يتم نصحك بذلك. إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، فمن الممكن أن تسبب زيلدافيت &nbsp;أثارا جانبية, إلا أنها لا تصيب كل من يتناول الدواء.</p><p>قم بزيارة الطبيب على الفور إذا تعرضت لأي من الأعراض الجانبية الشديدة والنادرة جدا التالي ذكرها بعد تناول هذا الدواء:</p><ul><li>الأزيز المفاجئ أو آلام في الصدرأو ضيق في التنفس أو صعوبة في التنفس</li><li>تورم الوجه أوالجفون أو الشفاه</li><li>تورم في اللسان والحلق والذي يسبب صعوبة كبيرة في التنفس.</li><li>تفاعلات جلدية شديدة وتشمل طفح جلدي شديد، وبثور واحمرار الجلد شاملاً عامة الجسم والحكة الشديدة والتنفط والتقشير وتورم الجلد والتهاب الأغشية المخاطية )متلازمة ستيفنز جونسون( أو غيرها من تفاعلات الحساسية.</li><li>نوبة قلبية، اضطراب ضربات القلب.</li><li>التهابات بالبنكرياس والتي قد تسبب آلام شديدة في البطن والظهر مصحوبة بالشعور بالإعياء الشديد.</li></ul><p>تم تسجيل ما يلي من الآثار الجانبية الشائعة. &nbsp; فلو تسبب أي منها في متاعب لك أو إذا استمرت لمدة تزيد عن أسبوع، توجب عليك الاتصال بالطبيب.</p><p>&nbsp;</p><p><strong>آثار جانبية شائعة: تصيب ما يتراوح من 1 إلى 10 من بين كل 100 من مستخدمي الدواء</strong></p><ul><li>الصداع، والدوار، والنعاس (وخاصة في بداية العلاج)</li><li>الخفقان (الإحساس بضربات قلبك) والفورة</li><li>ألم في البطن، والشعور بالرغبة في التقيؤ (الغثيان)</li><li>تورم الكاحل (الوذمة)، والإجهاد</li><li>وتشمل القائمة التالية آثاراً جانبية أخرى تم تسجيلها. فإذا تطور أي من هذه الآثار الجانبية إلى درجة خطيرة، أو إذا لاحظت أن ثمة آثار جانبية ليست مدرجة في هذه النشرة، يرجى اللجوء مباشرة لطبيبك المعالج أو الصيدلي.&nbsp;</li></ul><p>&nbsp;</p><p><strong>آثار غير شائعة: تصيب ما يتراوح من 1 إلى 10 من بين كل 1000 من مستخدمي الدواء</strong></p><ul><li>تقلبات في المزاج، والقلق، والاكتئاب، والأرق</li><li>الارتجاف، وخلل بالتذوق، والإغماء، والضعف</li><li>الإحساس بالتنميل أو الوخز في الأطراف، وفقدان الإحساس بالألم</li><li>اضطرابات بصرية، الرؤية المزدوجة، طنين في الأذنين</li><li>انخفاض ضغط الدم</li><li>العطس / سيلان الأنف الناجم عن التهاب بطانة الأنف (التهاب الأنف)</li><li>تغير عادات الإخراج، والإسهال، والإمساك، وعسر الهضم، وجفاف الفم والقيء (الإحساس بالاعتلال)</li><li>تساقط الشعر، وزيادة التعرق، وحكة في الجلد، بقع حمراء على الجلد, تغير لون الجلد</li><li>اضطراب في التبول، وزيادة الحاجة للتبول ليلا، وزيادة عدد مرات التبول.</li><li>عدم القدرة على إحداث الانتصاب، أو عدم الراحة أو تضخم الثدي لدى الرجال</li><li>الضعف والألم، والشعور بالإعياء</li><li>آلام المفاصل أو العضلات، وتقلص العضلات، وآلام الظهر</li><li>زيادة الوزن أو نقصانه</li></ul><p>&nbsp;</p><p><strong>آثار نادرة: تصيب ما يتراوح من 1 إلى 10 من بين كل 10000 من مستخدمي الدواء</strong></p><ul><li>الاختلاط</li></ul><p>&nbsp;</p><p><strong>آثار نادرة جدا: تصيب ما يقل عن واحد من بين كل 10000 من مستخدمي الدواء</strong></p><ul><li>انخفاض عدد خلايا الدم البيضاء، وانخفاض في الصفائح الدموية والذي &nbsp;قد يؤدي إلى كدمات غير معتادة أو سهولة النزف (تلف خلايا الدم الحمراء)</li><li>زيادة السكر في الدم (فرط سكر الدم)</li><li>اضطراب في الأعصاب الذي يمكن أن يسبب ضعف أو وخز أو خدر</li><li>السعال، وتورم اللثة</li><li>انتفاخات في البطن (التهاب المعدة)</li><li>اضطراب وظائف الكبد، التهاب الكبد (الالتهاب الكبدي)، اصفرار الجلد (اليرقان) وزيادة انزيمات الكبد والتي قد يكون لها تأثير على بعض الفحوصات الطبية</li><li>زيادة توتر العضلات</li><li>التهاب الأوعية الدموية، وغالبا مع طفح جلدي</li><li>الحساسية للضوء</li><li>اضطرابات تجمع بين التصلب والرعاش و / أو اضطرابات الحركة</li></ul><p>إذا تطور أي من الآثار الجانبية إلى درجة خطيرة، أو إذا لاحظت أن ثمة آثار جانبية ليست مدرجة في هذه النشرة، يرجى اللجوء مباشرة لطبيبك المعالج أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull; يحفظ بعيدا عن متناول وبصر الأطفال.<br />&bull; يخزن تحت درجة حرارة اقل من 30 درجة حرارة مئوية.<br />&bull; يخزن في العبوة الأصلية لحمايته من الضوء.<br />&bull; لا تستخدم الدواء بعد تاريخ انتهاء الصلاحية الوارد على العبوة بعد &quot;EXP&quot;. ويشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.&nbsp;<br />&bull; يحظر التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <ul><li>المادة الفعالة هي بيزيلات أملوديبين&nbsp;</li><li>باقي المواد هي السليولوز دقيق التبلور و اللاكتوز أحادي التموه و نشا الذرة و ستيارات المغنيسيوم (E470B).</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <ul><li dir="rtl"><strong>زيلدافيت 5 ملجم</strong> هي أقراص مستديرة الشكل ذات لون أصفر إلى أبيض. منقوش عليها &quot;APO&quot; على أحد الجانبين ومنقوش &quot;AML&quot; و&quot;5&quot; على الجانب الآخر. زيلدافيت &nbsp;5 ملجم متوفرة في علب أشرطة من الألومونيوم/بيه في سي/بيه في دي سي وتحتوي على 28 و 30 قرص.</li></ul><p>&nbsp;</p><ul><li dir="rtl"><strong>زيلدافيت 10 ملجم</strong> هي أقراص مستديرة الشكل ذات لون أصفر إلى أبيض. منقوش عليها &quot;APO&quot; على أحد الجانبين ومنقوش &quot;AML&quot; و&quot;10&quot; على الجانب الآخر. زيلدافيت 10 ملجم متوفرة في علب أشرطة من الألومونيوم/بيه في سي/بيه في دي سي وتحتوي على 14 و 30 قرص.</li></ul><p>&nbsp;</p><p>* قد لا يتم تسويق كافة أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق</strong><br />ابوتكس هولندا بي في ارشيمدسويج 22333 سي ان ليدن هولندا.</p><p>&nbsp;</p><p><strong>المصنع</strong><br />شركة أبوتكس، في مدينة تورنتو، مقاطعة أونتاريو، M9L 1T9 كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apo-Amlodipine Tablets 5 mg 
Apo-Amlodipine Tablets 10 mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apo-Amlodipine Tablets 5 mg: Each tablet contains 5 mg of amlodipine (as amlodipine besylate). Apo-Amlodipine Tablets 10 mg: Each tablet contains 10 mg of amlodipine (as amlodipine besylate).

Excipients:
For a full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet. 
5 mg tablet: White to off-white, round unscored tablets, imprinted APO on one side and AML over 5 on the other side. 

10 mg tablet: White to off-white, round unscored tablets, imprinted APO on one side and AML over 10 on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypertension.</p><p>Chronic stable angina pectoris</p><p>Vasospastic (Prinzmetal&rsquo;s) angina</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u>&nbsp;</strong></p><p><strong>Adults</strong></p><p>For both hypertension and angina the usual initial dose is 5 mg Apo-Amlodipine once daily which may be increased to a maximum dose of 10 mg depending on the individual patient&rsquo;s response.</p><p>In hypertensive patients, Apo-Amlodipine has been used in combination with a thiazide diuretic, alpha blocker, beta blocker, or an angiotensin converting enzyme inhibitor. For angina, Apo-Amlodipine may be used as monotherapy or in combination with other antianginal medicinal products in patients with angina that is refractory to nitrates and/or to adequate doses of beta blockers.</p><p>No dose adjustment of Apo-Amlodipine is required upon concomitant administration of thiazide diuretics, beta blockers, and angiotensin-converting enzyme inhibitors.</p><p>&nbsp;</p><p><strong><u>Special populations</u></strong></p><p><strong>Elderly</strong></p><p>Apo-Amlodipine used at similar doses in elderly or younger patients is equally well tolerated. Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><strong>Hepatic impairment</strong></p><p>Dosage recommendations have not been established in patients with mild to moderate hepatic impairment; therefore dose selection should be cautious and should start at the lower end of the dosing range (see sections 4.4 and 5.2). The pharmacokinetics of amlodipine have not been studied in severe hepatic impairment. Amlodipine should be initiated at the lowest dose and titrated slowly in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><strong>Renal impairment</strong></p><p>Changes in amlodipine plasma concentrations are not&nbsp;correlated with degree of renal impairment, therefore the normal dosage is recommended. Amlodipine is not dialysable.</p><p>&nbsp;</p><p><strong><u>Pediatric population</u></strong></p><p><strong>Children</strong><strong> </strong><strong>and</strong><strong> </strong><strong>adolescents</strong><strong> </strong><strong>with hypertension from 6 years to 17 years of age</strong></p><p>The recommended antihypertensive oral dose in pediatric patients ages 6-17 years is 2.5 mg once daily as a starting dose, up-titrated to 5 mg once daily if blood pressure goal is not achieved after 4 weeks. Doses in excess of 5 mg daily have not been studied in pediatric patients (see sections 5.1 and 5.2). Doses of amlodipine 2.5 mg are not possible with this medicinal product.</p><p>&nbsp;</p><p><strong>Children under 6 years old</strong></p><p>No data are available.</p><p>&nbsp;</p><p><strong><u>Method of administration</u></strong></p><p>Tablet for oral administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amlodipine is contraindicated in patients with:
-	hypersensitivity to dihydropyridine derivatives, amlodipine or to any of the excipients.
-	severe hypotension.
-	shock (including cardiogenic shock).
-	obstruction of the outflow tract of the left ventricle (e.g., high grade aortic stenosis).
-	haemodynamically unstable heart failure after acute myocardial infarction.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety and efficacy of amlodipine in hypertensive crisis has not been established.</p><p>&nbsp;</p><p><strong>Patients with cardiac failure</strong></p><p>Patients with heart failure should be treated with caution. In a long-term, placebo controlled study in patients with severe heart failure (NYHA class III and IV) the reported incidence of pulmonary oedema was higher in the amlodipine treated group than in the placebo group (see section 5.1).</p><p>Calcium channel blockers, including amlodipine, should be used with caution in patients with congestive heart failure, as they may increase the risk of future cardiovascular events and mortality.</p><p>&nbsp;</p><p><strong>Use in patients with impaired hepatic function</strong></p><p>The half life of amlodipine is prolonged and AUC values are higher in patients with impaired liver function; dosage recommendations have not been established. Amlodipine should therefore be initiated at the lower end of the dosing range and caution should be used, both on initial treatment and when increasing the dose. Slow dose titration and careful monitoring may be required in patients with severe hepatic impairment.</p><p>&nbsp;</p><p><strong>Use in elderly patients</strong></p><p>In the elderly increase of the dosage should take place with care (see sections 4.2 and 5.2).</p><p>&nbsp;</p><p><strong>Use in renal failure</strong></p><p>Amlodipine may be used in such patients at normal doses. Changes in amlodipine plasma concentrations are not correlated with degree of renal impairment. Amlodipine is not dialysable.</p><p>This product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Effects</strong><strong> </strong><strong>of other medicinal products on amlodipine</strong></p><p><em>CYP3A4 inhibitors:</em></p><p>Concomitant use of amlodipine with strong or moderate CYP3A4 inhibitors (protease inhibitors, azole antifungals, macrolides like erythromycin or clarithromycin, verapamil or diltiazem) may give rise to significant increase in amlodipine exposure. The clinical translation of these PK variations may be more pronounced in the elderly. Clinical monitoring and dose adjustment may thus be required.</p><p>&nbsp;</p><p><em>CYP3A4 inducers:</em></p><p>There is no data available regarding the effect of CYP3A4 inducers on amlodipine. The concomitant use of CYP3A4 inducers (e.g., rifampicin, hypericum perforatum) may give a lower plasma concentration of amlodipine. Amlodipine should be used with caution together with CYP3A4 inducers.</p><p>Administration of amlodipine with grapefruit or grapefruit juice is not recommended as bioavailability may be increased in some patients resulting in increased blood pressure lowering effects.</p><p>&nbsp;</p><p><em>Dantrolene (infusion)</em>: In animals, lethal ventricular fibrillation and cardiovascular collapse are observed in association with hyperkalemia after administration of verapamil and intravenous dantrolene. Due to risk of hyperkalemia, it is recommended that the co-administration of calcium channel blockers such as amlodipine be avoided in patients susceptible to malignant hyperthermia and in the management of malignant hyperthermia.</p><p>&nbsp;</p><p><strong>Effects of amlodipine on other medicinal products</strong></p><p>The blood pressure lowering effects of amlodipine add to the blood pressure-lowering effects of other medicinal products with antihypertensive properties.</p><p>In clinical interaction studies, amlodipine did not affect the pharmacokinetics of atorvastatin, digoxin, warfarin or cyclosporin.</p><p><em>Simvastatin</em>: Co-administration of multiple doses of 10 mg of amlodipine with 80 mg simvastatin resulted in a 77% increase in exposure to simvastatin compared to simvastatin alone. Limit the dose of simvastatin in patients on amlodipine to 20 mg daily.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy(category</em><em> </em><em>C)</em></p><p>The safety of amlodipine in human pregnancy has not been established.</p><p>In animal studies, reproductive toxicity was observed at high doses (see section 5.3).</p><p>Use in pregnancy is only recommended when there is no safer alternative and when the disease itself carries greater risk for the mother and foetus.</p><p>&nbsp;</p><p><strong><em>Breast-feeding</em></strong></p><p>It is not known whether amlodipine is excreted in breast milk. A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with amlodipine should be made taking into account the benefit of breast-feeding to the child and the benefit of amlodipine therapy to the mother.</p><p>&nbsp;</p><p><strong><em>Fertility</em></strong></p><p>Reversible biochemical changes in the head of spermatozoa have been reported in some patients treated by calcium channel blockers. Clinical data are insufficient regarding the potential effect of amlodipine on fertility. In one rat study, adverse effects were found on male fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amlodipine can have minor or moderate influence on the ability to drive and use machines.</p><p>If patients taking amlodipine suffer from dizziness, headache, fatigue or nausea the ability to react may be impaired. Caution is recommended especially at the start of treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary</strong><strong> </strong><strong>of the safety profile</strong></p><p>The most commonly reported adverse reactions during treatment are somnolence, dizziness, headache, palpitations, flushing, abdominal pain, nausea, ankle swelling, oedema and fatigue.</p><p>&nbsp;</p><p><strong>Tabulated list of adverse reactions</strong></p><p>The following adverse reactions have been observed and reported during treatment with amlodipine with the following frequencies: Very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &le;1/100); rare (&ge;1/10,000 to &le;1/1,000); very rare (&le;1/10,000).</p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:1032px"><tbody><tr><td style="width:358px"><p><strong>System</strong><strong> </strong><strong>organ</strong><strong> </strong><strong>class</strong></p></td><td style="width:84px"><p><strong>Frequency</strong></p></td><td style="width:589px"><p><strong>Adverse</strong><strong> </strong><strong>reactions</strong></p></td></tr><tr><td style="width:358px"><p><strong>Blood</strong><strong> </strong><strong>and</strong><strong> </strong><strong>lymphatic</strong><strong> </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td><td style="width:84px"><p>Very rare</p></td><td style="width:589px"><p>Leukocytopenia, thrombocytopenia</p></td></tr><tr><td style="width:358px"><p><strong>Immune</strong><strong> </strong><strong>system</strong><strong> </strong><strong>disorders</strong></p></td><td style="width:84px"><p>Very rare</p></td><td style="width:589px"><p>Allergic reactions</p></td></tr><tr><td style="width:358px"><p><strong>Metabolism and&nbsp;</strong><strong>nutrition</strong><strong> </strong><strong>disorders</strong></p></td><td style="width:84px"><p>Very rare</p></td><td style="width:589px"><p>Hyperglycaemia</p></td></tr></tbody></table><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2"><p><strong>Psychiatric</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Insomnia, mood changes (including anxiety), depression</p></td></tr><tr><td><p>Rare</p></td><td colspan="3"><p>Confusion</p></td></tr><tr><td rowspan="3"><p><strong>Nervous system disorders</strong></p></td><td><p>Common</p></td><td colspan="3"><p>Somnolence, dizziness, headache (especially at the beginning of the treatment)</p></td></tr><tr><td><p>Uncommon</p></td><td colspan="3"><p>Tremor, dysgeusia, syncope, hypoesthesia, paresthesia</p></td></tr><tr><td><p>Very rare</p></td><td colspan="3"><p>Hypertonia, peripheral neuropathy</p></td></tr><tr><td><p><strong>Eye</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Visual disturbance (including diplopia)</p></td></tr><tr><td><p><strong>Ear</strong><strong> </strong><strong>and</strong><strong> </strong><strong>labyrinth</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Tinnitus</p></td></tr><tr><td rowspan="2"><p><strong>Cardiac</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Common</p></td><td colspan="3"><p>Palpitations</p></td></tr><tr><td><p>Very rare</p></td><td colspan="3"><p>Myocardial infarction, arrhythmia (including bradycardia, ventricular tachycardia and atrial fibrillation)</p></td></tr><tr><td rowspan="3"><p><strong>Vascular</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Common</p></td><td colspan="3"><p>Flushing</p></td></tr><tr><td><p>Uncommon</p></td><td colspan="3"><p>Hypotension</p></td></tr><tr><td><p>Very rare</p></td><td colspan="3"><p>Vasculitis</p></td></tr><tr><td rowspan="2"><p><strong>Respiratory,&nbsp;</strong><strong>thoracic&nbsp;</strong><strong>and</strong><strong> </strong><strong>mediastinal</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Dyspnoea, rhinitis</p></td></tr><tr><td><p>Very rare</p></td><td colspan="3"><p>Cough</p></td></tr><tr><td rowspan="3"><p><strong>Gastrointestinal</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Common</p></td><td colspan="3"><p>Abdominal pain, nausea</p></td></tr><tr><td><p>Uncommon</p></td><td colspan="3"><p>Vomiting, dyspepsia, altered bowel habits (including diarrhoea and constipation), dry mouth</p></td></tr><tr><td><p>Very rare</p></td><td colspan="3"><p>Pancreatitis, gastritis, gingival hyperplasia</p></td></tr><tr><td><p><strong>Hepatobiliary</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Very rare</p></td><td colspan="3"><p>Hepatitis, jaundice, hepatic enzymes increased *</p></td></tr><tr><td rowspan="2"><p><strong>Skin and&nbsp;</strong><strong>subcutaneous</strong><strong> </strong><strong>tissue</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Alopecia, purpura, skin discolouration, hyperhidrosis, pruritus, rash, exanthema</p></td></tr><tr><td><p>Very rare</p></td><td colspan="3"><p>Angioedema, erythema multiforme, urticaria, exfoliative dermatitis, Stevens-Johnson syndrome, Quincke oedema, photosensitivity</p></td></tr><tr><td rowspan="2"><p><strong>Musculoskeletal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>and</strong><strong> </strong><strong>connective</strong><strong> </strong><strong>tissue</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Common</p></td><td colspan="3"><p>Ankle swelling</p></td></tr><tr><td><p>Uncommon</p></td><td colspan="3"><p>Arthralgia, myalgia, muscle cramps, back pain</p></td></tr><tr><td><p><strong>Renal</strong><strong> </strong><strong>and</strong><strong> </strong><strong>urinary disorders</strong></p></td><td><p>Uncommon</p></td><td rowspan="1" colspan="3"><p>Micturition disorder, nycturia, frequency increased urinary</p></td></tr><tr><td><p><strong>Reproductive system&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>and</strong><strong> </strong><strong>breast</strong><strong> </strong><strong>disorders</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Impotence, gynaecomastia</p></td></tr><tr><td rowspan="2"><p><strong>General</strong><strong> </strong><strong>disorders and administration&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; site conditions</strong></p></td><td><p>Common</p></td><td colspan="3"><p>Oedema, fatigue</p></td></tr><tr><td><p>Uncommon</p></td><td colspan="3"><p>Chest pain, asthenia, pain, malaise</p></td></tr><tr><td><p><strong>Investigations</strong></p></td><td><p>Uncommon</p></td><td colspan="3"><p>Weight increase, weight decrease</p></td></tr></tbody></table><p>* mostly consistent with cholestasis</p><p>Exceptional cases of extrapyramidal syndrome have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In humans experience with intentional overdose is limited.</p><p>&nbsp;</p><p><em>Symptoms</em></p><p>Available data suggest that gross overdosage could result in excessive peripheral vasodilatation and possibly reflex tachycardia. Marked and probably prolonged systemic hypotension up to and including shock with fatal outcome have been reported.</p><p>&nbsp;</p><p><em>Treatment</em></p><p>Clinically significant hypotension due to amlodipine overdosage calls for active cardiovascular support including frequent monitoring of cardiac and&nbsp; respiratory function, elevation of extremities and attention to circulating fluid volume and urine output.</p><p>A vasoconstrictor may be helpful in restoring vascular tone and blood pressure, provided that there is no contraindication to its use. Intravenous calcium gluconate may be beneficial in reversing the effects of calcium channel blockade.</p><p>Gastric lavage may be worthwhile in some cases. In healthy volunteers the use of charcoal up to 2 hours after administration of amlodipine 10 mg has been shown to reduce the absorption rate of amlodipine.</p><p>Since amlodipine is highly protein-bound, dialysis is not likely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group:</p><p>Calcium channel blockers, selective calcium channel blockers with mainly vascular effects.</p><p>ATC-code: C08C A01</p><p>Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.</p><p>The mechanism of the antihypertensive action of amlodipine is due to a direct relaxant effect on vascular smooth muscle. The precise mechanism by which amlodipine relieves angina has not been fully determined but amlodipine reduces total ischaemic burden by the two following actions:</p><ol><li>Amlodipine dilates peripheral arterioles and thus, reduces the total peripheral resistance (afterload) against which the heart works. Since the heart rate remains stable, this unloading of the heart reduces myocardial energy consumption and oxygen requirements.</li><li>The mechanism of action of amlodipine also probably involves dilatation of the main coronary arteries and coronary arterioles, both in normal and ischaemic regions. This dilatation increases myocardial oxygen delivery in patients with coronary artery spasm (Prinzmetal&#39;s or variant angina).</li></ol><p>In patients with hypertension, once daily dosing provides clinically significant reductions of blood pressure in both the supine and standing positions throughout the 24-hour interval. Due to the slow onset of action, acute hypotension is not a feature of amlodipine administration.</p><p>In patients with angina, once daily administration of amlodipine increases total exercise time, time to angina onset, and time to 1mm ST segment depression, and decreases both angina attack frequency and glyceryl trinitrate tablet consumption.</p><p>Amlodipine has not been associated with any adverse metabolic effects or changes in plasma lipids and is suitable for use in patients with asthma, diabetes, and gout.</p><p>&nbsp;</p><p><strong>Use in patients with coronary artery disease (CAD)</strong></p><p>The effectiveness of amlodipine in preventing clinical events in patients with coronary artery disease (CAD) has been evaluated in an independent, multi-centre, randomized, double- blind, placebo-controlled study of 1997 patients; Comparison of Amlodipine vs. Enalapril to Limit Occurrences of Thrombosis (CAMELOT).</p><p>Of these patients, 663 were treated with amlodipine 5-10 mg, 673 patients were treated with enalapril 10- 20 mg, and 655 patients were treated with placebo, in addition to standard care of statins, beta-blockers, diuretics and aspirin, for 2 years.</p><p>The key efficacy results are presented in Table 1. The results indicate that amlodipine treatment was associated with fewer hospitalizations for angina and revascularization procedures in patients with CAD.<!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><span style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="_x0000_s1032" style='width:484.2pt;
 height:1.1pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="9684,22">
 <v:group id="_x0000_s1033" style='position:absolute;left:11;top:11;width:9663;
  height:2' coordorigin="11,11" coordsize="9663,2">
  <v:shape id="_x0000_s1034" style='position:absolute;left:11;top:11;width:9663;
   height:2' coordorigin="11,11" coordsize="9663,0" path="m11,11r9662,e"
   filled="f" strokeweight="1.06pt">
   <v:path arrowok="t"/>
  </v:shape></v:group><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="647" height="3" src="file:///C:/Users/ahmed/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:1.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
Arial'><v:shape id="_x0000_i1025" type="#_x0000_t75" style='width:484.2pt;
 height:1.1pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p><strong>Table 1. Incidence of significant clinical outcomes for CAMELOT</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td>&nbsp;</td><td rowspan="1" colspan="3"><p><u>Cardiovascular event rates,</u></p><p><u>No.&nbsp;(%)</u></p></td><td rowspan="1" colspan="2"><p><u>Amlodipine vs Placebo</u></p></td></tr><tr><td><p>Outcomes</p></td><td><p>Amlopidine</p></td><td><p>Placebo</p></td><td><p>Enalapril</p></td><td><p>Hazard Ratio</p><p>(95% CI)</p></td><td><p><em>P </em>Value</p></td></tr><tr><td><p><u>Primary Endpoint</u></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Adverse cardiovascular events</p></td><td><p>110 (16.6)</p></td><td><p>151 (23.1)</p></td><td><p>136 (20.2)</p></td><td><p>0.69 (0.54-0.88)</p></td><td><p>.003</p></td></tr><tr><td><p><u>Individual Components</u></p></td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td><p>Coronary revascularization</p></td><td><p>78 (11.8)</p></td><td><p>103 (15.7)</p></td><td><p>95 (14.1)</p></td><td><p>0.73 (0.54-0.98)</p></td><td><p>.03</p></td></tr><tr><td><p>Hospitalization for angina</p></td><td><p>51 (7.7)</p></td><td><p>84 (12.8)</p></td><td><p>86 (12.8)</p></td><td><p>0.58 (0.41-0.82)</p></td><td><p>.002</p></td></tr><tr><td><p>Nonfatal MI</p></td><td><p>14 (2.1)</p></td><td><p>19 (2.9)</p></td><td><p>11 (1.6)</p></td><td><p>0.73 (0.37-1.46)</p></td><td><p>.37</p></td></tr><tr><td><p>Stroke or TIA</p></td><td><p>6 (0.9)</p></td><td><p>12 (1.8)</p></td><td><p>8 (1.2)</p></td><td><p>0.50 (0.19-1.32)</p></td><td><p>.15</p></td></tr><tr><td><p>Cardiovascular death</p></td><td><p>5 (0.8)</p></td><td><p>2 (0.3)</p></td><td><p>5 (0.7)</p></td><td><p>2.46 (0.48-12.7)</p></td><td><p>.27</p></td></tr><tr><td><p>Hospitalization for CHF</p></td><td><p>3 (0.5)</p></td><td><p>5 (0.8)</p></td><td><p>4 (0.6)</p></td><td><p>0.59 (0.14-2.47)</p></td><td><p>.46</p></td></tr><tr><td><p>Resuscitated cardiac arrest</p></td><td><p>0</p></td><td><p>4 (0.6)</p></td><td><p>1 (0.1)</p></td><td><p>NA</p></td><td><p>.04</p></td></tr><tr><td><p>New-onset peripheral vascular disease</p></td><td><p>5 (0.8)</p></td><td><p>2 (0.3)</p></td><td><p>8 (1.2)</p></td><td><p>2.6 (0.50-13.4)</p></td><td><p>.24</p></td></tr></tbody></table><p>Abbreviations: CHF, congestive heart failure; CI, confidence interval; MI, myocardial infarction; TIA, transient ischemic attack.</p><p>&nbsp;</p><p><strong>Use in patients with heart failure</strong></p><p>Haemodynamic studies and exercise based controlled clinical trials in NYHA Class II-IV heart failure patients have shown that amlodipine did not lead to clinical deterioration as measured by exercise tolerance, left ventricular ejection fraction and clinical symptomatology.</p><p>A placebo controlled study (PRAISE) designed to evaluate patients in NYHA Class Ill-IV heart failure receiving digoxin, diuretics and ACE inhibitors has shown that amlodipine did not lead to an increase in risk of mortality or combined mortality and morbidity with heart failure.</p><p>In a follow-up, long term, placebo controlled study (PRAISE-2) of amlodipine in patients with NYHA III and IV heart failure without clinical symptoms or objective findings suggestive of underlying &nbsp;ischaemic disease, on stable doses of ACE inhibitors, digitalis, and diuretics, amlodipine had no effect on total cardiovascular mortality. In this same population amlodipine was associated with increased reports of pulmonary oedema.</p><p>&nbsp;</p><p><strong><u>Treatment to prevent heart attack trial (ALLHAT)</u></strong></p><p>A randomized&nbsp; double-blind morbidity-mortality study called the&nbsp; Antihypertensive&nbsp; and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) was performed to compare newer drug therapies: amlodipine 2.5-10 mg/d (calcium channel blocker) or lisinopril 10-40 mg/d (ACE-inhibitor) as first-line therapies to that of the thiazide-diuretic, chlorthalidone 12.5-25 mg/d in mild to moderate hypertension.&rdquo;</p><p>A total of 33,357 hypertensive patients aged 55 or older were randomized and followed for a mean of 4.9 years.</p><p>The patients had at least one additional CHD risk factor, including: previous myocardial infarction or stroke (&gt; 6 months prior to enrollment) or documentation of other atherosclerotic CVD (overall 51.5%), type 2 diabetes (36.1%), HDL-C &lt; 35 mg/dL (11.6%), left ventricular hypertrophy diagnosed by electrocardiogram or echocardiography (20.9%), current cigarette smoking (21.9%).</p><p>The primary endpoint was a composite of fatal CHD or non-fatal myocardial infarction.</p><p>There was no significant difference in the primary endpoint between amlodipine-based therapy and chlorthalidone-based therapy: RR 0.98 95% CI (0.90-1.07) p=0.65.</p><p>Among secondary endpoints, the incidence of heart failure (component of a composite combined cardiovascular endpoint) was significantly higher in the amlodipine group as compared to the chlorthalidone group (10.2% vs. 7.7%, RR 1.38, 95% CI [1.25-1.52] p&lt;0.001).</p><p>However, there was no significant difference in all-cause mortality between amlodipine-based therapy and chlorthalidone-based therapy. RR 0.96 95% CI [0.89-1.02] p=0.20.</p><p>&nbsp;</p><p><strong><u>Use in children (aged 6 years and older)</u></strong></p><p>In a study involving 268 children aged 6-17 years with predominantly secondary hypertension, comparison of a 2.5mg dose, and 5.0 mg dose of amlodipine with placebo, showed that both doses reduced Systolic Blood Pressure significantly more than placebo. The difference between the two doses was not statistically significant.</p><p>The long-term effects of amlodipine on growth, puberty and general development have not been studied. The long-term efficacy of amlodipine on therapy in childhood to reduce cardiovascular morbidity and mortality in adulthood have also not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Absorption,</strong><strong> distribution, plasma protein binding</strong>: After oral administration of therapeutic doses, amlodipine is well absorbed with peak blood levels between 6-12 hours post dose.</p><p>Absolute bioavailability has been estimated to be between 64 and 80%. The volume of distribution is approximately 21 I/kg. <em>In vitro </em>studies have shown that approximately 97.5% of circulating amlodipine is bound to plasma proteins.</p><p>The bioavailability of amlodipine is not affected by food intake.</p><p>&nbsp;</p><p><strong>Biotransformation/elimination</strong>: The terminal plasma elimination half life is about 35-50 hours and is consistent with once daily dosing. Amlodipine is extensively metabolised by the liver to inactive metabolites with 10% of the parent compound and 60% of metabolites excreted in the urine.</p><p>&nbsp;</p><p><strong>Use in hepatic impairment</strong></p><p>Very limited clinical data&nbsp; are available regarding amlodipine administration in patients with hepatic impairment. Patients with hepatic insufficiency have decreased clearance of amlodipine resulting in a longer half-life and an increase in AUC of approximately 40-60%.</p><p>&nbsp;</p><p><strong>Use in the elderly</strong></p><p>The time to reach peak plasma concentrations of amlodipine is similar in elderly and younger subjects. Amlodipine clearance tends to be decreased with resulting increases in AUC and elimination half-life in elderly patients. Increases in AUC and elimination half-life in patients with congestive heart failure were as expected for the patient age group studied.</p><p>&nbsp;</p><p><strong>Use in children</strong></p><p>A population PK study has been conducted in 74 hypertensive children aged from 1 to 17 years (with 34 patients aged 6 to 12 years and 28 patients aged 13 to 17 years) receiving amlodipine between 1.25 and 20 mg given either once or twice daily.</p><p>In children 6 to 12 years and in adolescents 13-17 years of age the typical oral clearance (CL/F) was 22.5 and 27.4 L/hr respectively in males and 16.4 and 21.3 L/hr respectively in females.</p><p>Large variability in exposure between individuals was observed. Data reported in children below 6 years is limited.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Reproductive</strong><strong> </strong><strong>toxicology</strong></p><p>Reproductive studies in rats and mice have shown delayed date of delivery, prolonged duration of labour and decreased pup survival at dosages approximately 50 times greater than the maximum recommended dosage for humans based on mg/kg.</p><p>&nbsp;</p><p><strong>Impairment of fertility</strong></p><p>There was no effect on the fertility of rats treated with amlodipine (males for 64 days and females 14 days prior to mating) at doses up to 10 mg/kg/day (8 times* the maximum recommended human dose of 10 mg on a mg/m2 basis). In another rat study in which male rats were treated with amlodipine besylate for 30 days at a dose comparable with the human dose based on mg/kg, decreased plasma follicle-stimulating hormone and testosterone were found as well as decreases in sperm density and in the number of mature spermatids and Sertoli cells.</p><p>&nbsp;</p><p><strong>Carcinogenesis, mutagenesis</strong></p><p>Rats and mice treated with amlodipine in the diet for two years, at concentrations calculated to provide daily dosage levels of 0.5, 1.25, and 2.5 mg/kg/day showed no evidence of carcinogenicity. The highest dose (for mice, similar to, and for rats twice* the maximum recommended clinical dose of 10 mg on a mg/m2 basis) was close to the maximum tolerated dose for mice but not for rats.</p><p>Mutagenicity studies revealed no drug related effects at either the gene or chromosome levels.</p><p>*Based on patient weight of 50 kg</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose (E460),</p><p>Lactose monohydrate,</p><p>Maize starch &amp;</p><p>Magnesium stearate (E470b).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30⁰C in the original package, in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Apo-Amlodipine Tablets 5 mg, tablets: Blister packs of aluminium/PVC/PVDC with 28 or 30 tablets.</p><p>Apo-Amlodipine Tablets 10 mg, tablets: Blister packs of aluminium/PVC/PVDC with 14 or 30 tablets.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Apotex Nederland BV 
Archimedesweg 2 
2333 CN Leiden 
The Netherlands.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2014
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>